Member Info for JoeyDiamond

Thanks Scinv/Ghia that certainly explains the confusion.

The trial design says 12 MIU is the concentration size in P3, it was 6 MIU I believe in the P2.

It mentions removal of the lower dose arm which I persume is the 1 syringe, so to me look like they using the two syringe approach here in the P3.

So looks to me the double syringe approach is still being used?

Graking the P3 trial is aimed at people in hospital (WHO Ord scale 4) so there will be no shortage of volunteers.

Its the low dose arm that has been removed from the P3 trial. All people will get double dose 12 MIU of the drug.

Hope so we been waiting along time for this resistance level to break!

I hope you guys are right ;)

I certainly hope you are right Doc would obviously love dosing to start next week.

I am just pointing out a possible reason why it may not start next week.

Staffing in the NHS over Xmas is difficult as many people will have time off and they are under the cosh with work loads. It may be seen as a risk to the dosing regimine under such pressures. The data commitee may be off work etc. Im pointing out there is obvious risk over Xmas week so do not be surprised if the first dose is not next week.

On P2 trial after approvals RNS was received the dosing started the following week on a Tuesday.

However with it being Xmas next week I would pencil in 29th Dec as possible first dosing.

All the shorters have turned back up on the board desperately trying to deramp, what a blood bath for them :)

Think thats due to it being double dose strength, orginal SNG001 low dose arm dropped :)

https://twitter.com/TheLancet/status/1339150879845445634

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32334-5/fulltext?utm_campaign=lancet&utm_content=149159120&utm_medium=social&utm_source=twitter&hss_channel=tw-27013292

Two phase 1 studies show, for the first time, the feasibility of using allogeneic, genome-edited CAR T cells to treat patients with aggressive #leukaemia.

Interpretation
These two studies show, for the first time, the feasibility of using allogeneic, genome-edited CAR T cells to treat patients with aggressive leukaemia. UCART19 exhibited in-vivo expansion and antileukaemic activity with a manageable safety profile in heavily pretreated paediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia. The results this study are an encouraging step forward for the field of allogeneic CAR T cells, and UCART19 offers the opportunity to treat patients with rapidly progressive disease and where autologous CAR-T-cell therapy is unavailable.

Oxford - another scientific update including N501Y

https://twitter.com/GuptaR_lab/status/1338610098663526402

Structural analyses of the H69/V70 deletions in the NTD suggests a conformational change of the exposed loop by 6.5A, which we hypothesise may effect a conformational change in the RBD (receptor binding domain).

Conspiracy theory from on twitter from a scientist ;/

The virus did originate from the Wuhan lab but it was accidental. The problem with the Wuhan lab is it does not have high grade incinerators so any animal carcasses were picked up by a 3rd party company to dispose of.

This 3rd party company was selling the carcasses to the nearby market to make extra money on the side instead of actually disposing of them correctly. Hence the virus appeared to originate from the market.

https://www.cogconsortium.uk/news_item/update-on-new-sars-cov-2-variant-and-how-cog-uk-tracks-emerging-mutations/

Latest update from COG-UK

The variant described today in the House of Commons contains a novel set of mutations associated with a lineage spreading rapidly in the South East of England (and more widely) that is the subject of ongoing investigations by the UK Public Health Agencies, coordinated by Public Health England and supported by COG-UK. This variant carries a set of mutations including an N501Y mutation in the receptor binding motif of the Spike protein that the virus uses to bind to the human ACE2 receptor.

Efforts are under way to confirm whether or not any of these mutations are contributing to increased transmission. There is currently no evidence that this variant (or any other studied to date) has any impact on disease severity, or that it will render vaccines less effective, although both questions require further studies performed at pace. We will provide further updates as our investigations proceed.

Depends on the dosage size. In the P3 trial the double dose arm is 12 MIU, if this proves to have higher efficacy then potential treatment would then cost over £2000 using those examples.

Shan, all the major vaccines are targeting the spike protein so a mutation could render one of/all the vaccines ineffective.

The chance is very small according to Phizer so the key word is their vaccine 'should' still cover this new variant. However its unknown at this stage until further testing.

However a mutation increasing ACE2 receptor binding is probably the one they didn't want to see, hence Han**** announcing it today. Other variants have largely been ignored and not mentioned by govt so this one must have them a bit worried.

Im glad he is linking the same articles this very board posted about a couple of months ago :)

Tomorrow there could be results from the Rebif ACTT trial https://clinicaltrials.gov/ct2/show/NCT04492475 so could be a bit of pre-empting / timing with this post with interferons.

We shall see :)

https://twitter.com/firefoxx66/status/1338533710178775047

Here is some more info on the new SARS-CoV-2 variant.

Variant mainly detected in the UK and Denmark.
The mutation is on the spike protein.
Suspect mutation may increase ACE2 receptor binding.

Early days and more investigation required but you can see why this variant has got scientists attention.

Funny we had this question on the term variant and strain the other day on twitter. In virus terms a variant and strain are quite different according to a well known Dr on twitter.

A new strain is bad as it contains mutations that fundamentally change the virus functionally and this could lead to it evading antibodies etc. ie vaccine may no longer work.
A variant is minor change to the virus but functionally stays the same. So unlikely to make any difference to a vaccine.

Analogy used on twitter is 'I think of this like apple varieties. For strains, Red delicious and Honeycrisp are both apples but they have unique flavor, texture, skin color and thickness, aroma, etc.

Variants are equivalent to a Red Delicious that’s a slightly different shape from another Red Delicious.

I know Azithromycin was one of the 5 drugs chosen for Recovery trials back in April. Bear in mind it costs only a couple of quid and is easy to produce made it a decent candidate on these reasons alone.

There were some trials/theories thinking it could help prevent viral spread despie it being an antibiotic.

However it is useful for treating bacterial infections caused by covid-19 complications due to weakened immune systems.